Teva's Ajovy, chasing Amgen and Lilly drugs, gains steam after autoinjector rollout

Ajovy
After its auto-injector approval earlier this year, sales for Teva's Ajovy are picking up. (Teva)

Upon its FDA approval in 2018, Teva’s migraine prevention medicine Ajovy faced tough prospects as it trailed a rival into the market with a less desirable delivery method. Nearly two years later, with an approval for an autoinjector device in hand, Teva's launch is beginning to kick into gear. 

During the second quarter, Ajovy's North American sales grew 50% to $34 million, and Teva CEO Kare Schultz said on a conference call he expects sales to keep increasing. Teva set out to win around 25% of the market, and since the auto-injector nod, the company’s share of prescriptions for patients starting treatment “has continued to grow significantly per month and per week," the CEO said.

RELATED: Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds? 

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The drug has also launched in Canada and Europe, as well, and scored reimbursement in 16 countries worldwide, Schultz said. He told analysts the drug’s sales will “slowly … start to add up” to hundreds of millions of dollars per year.

Based on recent prescription trends, analysts seem to agree. The med's sales are now annualizing at about $210 million, Jefferies analysts wrote in a note to clients after looking at current prescription numbers. Total prescriptions are up 17% this quarter, according to a separate note from J.P. Morgan analysts. 

And while the medicine picked up momentum in the second quarter, July looked even better, Schultz added.

Ajovy originally won approval in a prefilled syringe, which left the drug at a “modest disadvantage” in the market, with patients forced to get over the “psychological hurdle” of a syringe, RBC Capital Markets analyst Randall Stanicky wrote last spring.

RELATED: With Vyepti launch, Lundbeck aims to overcome challenges in crowded migraine field: exec 

As a new growth driver, Ajovy is an important launch for Teva following major cost cuts at the company. But the drug trailed Amgen’s Aimovig into the market and hasn’t been able to match the sales of its rivals. Now, a fourth company is in the CGRP migraine prevention market in Lundbeck. That drugmaker recently scored approval for Vyepti, a 30-minute infusion administered every three months. 

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.